source
- Novartis and Bristol Myers pause autoimmune CAR-T trials after safety concernsNovartis announced a temporary hold on its personalized CAR-T therapy rap-cel after three patients experienced immune effector cell-associated hemophagocytic syndrome, a rare and potentially life-t…
- Arrowhead’s plozasiran shows favorable safety in severe hypertriglyceridemia late-stage trialsArrowhead presented late-stage data for its RNA interference therapy plozasiran, marketed as Redemplo, in severe hypertriglyceridemia at the European Society of Cardiology 2026 meeting in Munich.…